October 22, 2003
GENELABS TECHNOLOGIES COMPLETES PUBLIC OFFERING OF COMMON STOCK

October 17, 2003
Genelabs Announces Pricing of Public Offering of Common Stock

October 1, 2003
Genelabs Technologies, Inc. Announces Proposed Offering Of up to 15 Million Shares of Common Stock

September 26, 2003
GENELABS PROVIDES UPDATE ON PRESTARA™ DEVELOPMENT

September 16, 2003
GENELABS TECHNOLOGIES PRESENTS ANTIFUNGAL IN VIVO EFFICACY DATA AT THE 43RD ANNUAL ICAAC

August 14, 2003
GENELABS TECHNOLOGIES, INC. REPORTS SECOND QUARTER AND SIX MONTH 2003 FINANCIAL RESULTS

August 1, 2003
Genelabs Technologies Raises $2.7 Million in Private Placement Financing

June 10, 2003
Genelabs Announces Voting Results from Annual Meeting of Shareholders

June 10, 2003
Genelabs to Provide Corporate Update at Annual Shareholder Meeting

May 15, 2003
GENELABS TECHNOLOGIES, INC. REPORTS 2003 FIRST QUARTER FINANCIAL RESULTS

May 2, 2003
Genelabs Technologies Raises $8.1 Million in Private Placement Financing

April 3, 2003
GENELABS PRESENTS LUPUS CLINICAL TRIAL DATA AT A JOINT MEETING OF THE BRITISH SOCIETY FOR RHEUMATOLOGY AND THE SOCIÉTÉ FRANÇAISE DE RHUMATOLOGIE

March 21, 2003
Genelabs Technologies Presents Animal Efficacy Data For its Antifungal Preclinical Candidate

February 21, 2003
Genelabs Concentrates Workforce on Key Research and Development Programs

February 18, 2003
Genelabs Technologies Encouraged by Confirmation that the Hepatitis G Virus Prolongs Survival of AIDS Patients

January 9, 2003
Genelabs’ European Marketing Authorization Application for Lupus Drug Accepted for Review by EMEA

January 8, 2003
Genelabs Initiates Confirmatory Phase III Trial for Prestara™

© Genelabs Technologies, Inc. All rights reserved. - Terms of Use